赛诺医疗携神经介入创新新品亮相东方脑血管病大会2024

Company Updates - The company's subsidiary, Sinomed Shenchang, showcased its innovative products, including the self-expanding intracranial drug-coated stent and the flow-diverter coated mesh stent, at the OCIN 2024 conference [1] - The company's self-developed COMETIU stent, the world's first self-expanding intracranial drug-coated stent, passed the NMPA's innovative medical device approval in April 2024 and was submitted for domestic medical device registration in May 2024 [1] - The COMETIU stent demonstrated a post-operative 6-month in-stent restenosis (ISR) rate of 1.72% and a stroke or death rate of 3.13% in clinical trials [1] - The company's flow-diverter coated mesh stent, another innovative product, showed promising results in a single-center clinical trial at Wuhan Union Hospital, with 27 patients and 29 aneurysms included in the study [1] - The flow-diverter coated mesh stent achieved a Raymond I rate of 88.46% and a Raymond I+II rate of 87.88% at 6 months, and a Raymond I+II rate of 92.41% at 1 year, with no post-operative stroke events reported [2] - The company's flow-diverter coated mesh stent is the first in China to be delivered via a 017 system, featuring a new alloy material, proprietary electronic coating grafting technology, and the smallest delivery profile globally [2] - The company's neurovascular business is entering a harvest period with the upcoming market entry of its innovative products, including the flow-diverter coated mesh stent [3] Industry Insights - Intracranial atherosclerotic stenosis (ICAS) is a common cause of ischemic stroke, particularly in Asian populations, with higher recurrence rates as stenosis severity increases [1] - Intracranial stent placement has become a highly anticipated treatment for ICAS, with the COMETIU stent significantly reducing post-operative restenosis rates and stroke or death rates [1] - The company's product pipeline, including the NOVA intracranial drug-eluting stent approved in 2021 and the intracranial thrombectomy stent approved in the first half of 2023, positions it to meet diverse stent needs for ischemic stroke intervention [2]